Q2 EPS Forecast for Larimar Therapeutics Boosted by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Investment analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for Larimar Therapeutics in a report issued on Wednesday, April 30th. Leerink Partnrs analyst J. Park now expects that the company will earn ($0.52) per share for the quarter, up from their prior estimate of ($0.61). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics' Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.28) EPS, FY2026 earnings at ($2.61) EPS, FY2027 earnings at ($2.34) EPS and FY2028 earnings at ($1.26) EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04).

A number of other research firms also recently commented on LRMR. Truist Financial began coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price objective on the stock. Robert W. Baird dropped their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 25th. HC Wainwright boosted their price objective on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, March 25th. Guggenheim restated a "buy" rating and issued a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Finally, Citigroup reiterated a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Larimar Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $19.63.

Larimar Therapeutics Price Performance

NASDAQ:LRMR remained flat at $2.24 during trading hours on Monday. The company had a trading volume of 168,842 shares, compared to its average volume of 751,119. Larimar Therapeutics has a 52-week low of $1.61 and a 52-week high of $11.20. The company has a market capitalization of $143.42 million, a PE ratio of -1.95 and a beta of 0.93. The company has a 50-day simple moving average of $2.31 and a two-hundred day simple moving average of $4.10.

Institutional Trading of Larimar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its holdings in shares of Larimar Therapeutics by 15.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company's stock worth $24,936,000 after purchasing an additional 876,431 shares during the period. Blue Owl Capital Holdings LP raised its position in Larimar Therapeutics by 11.7% during the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company's stock worth $18,007,000 after buying an additional 486,211 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in shares of Larimar Therapeutics by 23.5% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company's stock worth $8,127,000 after acquiring an additional 399,123 shares during the period. Alyeska Investment Group L.P. boosted its holdings in shares of Larimar Therapeutics by 38.6% in the fourth quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company's stock valued at $3,808,000 after acquiring an additional 273,920 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Larimar Therapeutics by 278.8% during the fourth quarter. Cubist Systematic Strategies LLC now owns 233,873 shares of the company's stock worth $905,000 after acquiring an additional 172,131 shares during the period. 91.92% of the stock is owned by hedge funds and other institutional investors.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.